Clareo Health | A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy
A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Astellas Pharma Inc
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Subject is diagnosed with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, signet cell or small cell histology.
Subject with established diagnosis of metastatic castration-resistant prostate carcinoma.
Subject is being newly initiated on Xtandi treatment (Enzalutamide).
Subject has an estimated life expectancy of ≥ 6 months.
Subject agrees not to participate in another interventional study while participating in the present study.
You may not be if
Subject participating or planning to participate in any interventional drug trial during the course of this trial.
Subject has received investigational study within 28 days or 5 half-lives, whichever is longer, prior to screening.
Subject has any condition which makes the subject unsuitable for study participation.
